Androgen Replacement in Women: A Commentary
The DOI matches its OpenAlex record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
There is increasing evidence to suggest that many postmenopausal women experience symptoms alleviated by androgen therapy and that such symptoms may be secondary to androgen deficiency. Affected women complain of fatigue, low libido, and diminished well-being, symptoms easily and frequently attributed to psychosocial and environmental factors. When such symptoms occur in the setting of low circulating bioavailable testosterone, testosterone replacement results in significant improvement in symptomatology and, hence, quality of life for the majority of women. Whether the apparent therapeutic effects of testosterone replacement are mediated by testosterone and its metabolite 5alpha- dihydrotestosterone or are a consequence of aromatization to estrogen is not known. Despite the paucity of data regarding its effects, inclusion of testosterone in postmenopausal hormone replacement regimens is not uncommon and is likely to become more widespread with the availability of preparations developed specifically for women. Other novel and even more controversial potential indications for androgen therapy in women are currently being evaluated. These include use in women with premature ovarian failure, premenopausal androgen deficiency symptoms, postmenopausal and glucocorticosteroid-related bone loss, alleviation of wasting syndrome secondary to human immunodeficiency virus infection, and management of premenstrual syndrome. The aim of this commentary is to very briefly review the rationale for the use of testosterone in women, create awareness of some of the therapeutic options available in various countries, and stimulate discussion of this important aspect of women's health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle
ABRAHAM, G. E. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-39-2-340 · Cited by 436
Zumoff, B., Strain, G. W., Miller, L. K., & Rosner, W. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.4.7714119 · Cited by 392 · cited 1×
“Circulating androgen levels [total testosterone, free testosterone, dehydroepiandrosterone (DHEA), and DHEA sulfate (DHEA-S)] in women fall continuously with age (4, 5).”
BackgroundAromatase activity in the rat brain: Hormonal regulation and sex differences
Roselli, C. E., & Resko, J. A. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90254-t · Cited by 178
Bloch, M., Schmidt, P. J., Su, T.-P., Tobin, M. B., & Rubinow, D. R. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00403-x · Cited by 100 · cited 1×
“Variations in testosterone levels during the menstrual cycle may influence behavioral changes such as those seen in PMS, and significantly lower levels of testosterone throughout the menstrual cycle have been reported in women who suffer from PMS compared with controls (33, 34).”
ResultEvidence for diminished midcycle ovarian androgen production in older reproductive aged women
Mushayandebvu, T., Castracane, V. D., Gimpel, T., Adel, T., & Santoro, N. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58203-x · Cited by 94
Birrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M., & Tilley, W. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1572 · Cited by 87 · cited 1×
“There are also some data to suggest that the mechanism by which high dose medroxyprogesterone acetate has a therapeutic effect on breast cancer is mediated via the androgen receptor (48).”
Background
Cited by
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
“Limited data also suggest that combined estrogen and T replacement may result in an additional increase in bone density compared with estrogen alone (382, 384).”
BackgroundAndrogens and Coronary Artery Disease
Wu, F. C. W., & von Eckardstein, A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0025 · Cited by 592
Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544
Gender differences in cardiovascular disease
Gao, Z., Chen, Z., Sun, A., & Deng, X. (2019) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2019.100025 · Cited by 373
Metadata
- Authors
- Davis, S. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- Oxford University Press
- Published
- 1999-06-01
- Volume
- 84
- Issue
- 6
- Pages
- 1886-1891
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2054264838
- Cited by
- 134
- References
- 6
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.